A Female Viagra?
Women with low libido get a boost from a new drug
By Emily Anthes
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Women who suffer from chronically low levels of sexual desire may soon be able to fix the problem with a pill. In a review of three recent clinical trials, scientists determined that after 24 weeks of treatment with the drug flibanserin, women reported significantly more sexual desire and an increase in satisfactory sexual encounters. The drug was initially developed as an antidepressant, and although it failed to alter mood in trials, researchers noticed it seemed to be helping women with low sex drives. How the drug works is not yet entirely clear, but it is known to alter the levels of serotonin in the brain. Although more trials are needed before flibanserin could become available commercially, it shows promise as the first drug demonstrated to treat low libido in women—the most common sexual problem in females—by targeting the brain.
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber
